News Briefing channel feed

Amy­lyx to move for­ward with ALS pro­gram in Eu­rope, but FDA wants an­oth­er look; Hu­ma­cyte adds $50M in debt fi­nanc­ing

5 years ago

Re­cur­sion lays out $300M+ goal in IPO terms; Evotec and Bris­tol My­ers team up to spin out Ger­man re­search

5 years ago

Jazz Phar­ma­ceu­ti­cals push­es to ex­pand la­bel on Xy­wav; FDA eyes Oc­to­ber for de­ci­sion on Seagen's lat­est ADC

5 years ago

Seat­tle-based Remiges Ven­tures to launch in­cu­ba­tor af­ter heavy in­vest­ment from Japan; Schrödinger signs lease on new home in Man­hat­tan

5 years ago

Bio­gen ac­quires rights for po­ten­tial Actem­ra biosim­i­lar; Roy­al­ty Phar­ma buys lumasir­an roy­al­ty stream for up to $240M

5 years ago

Vac­citech con­fi­den­tial­ly files for Nas­daq IPO — re­port; Sanofi recom­mits to so­cial caus­es, launch­es glob­al non­prof­it

5 years ago

In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up with Va­lence to pro­vide AI dis­cov­ery plat­form

5 years ago

Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

5 years ago

Unit­ed Ther­a­peu­tics bags a new OK on Ty­va­so, with block­buster ex­pec­ta­tions; Gilead goes back to Ab­Celler­a's well with a set of fresh tar­gets

5 years ago

Bausch Health sells off Amoun for $740M; Achilles de­buts on Nas­daq with $175.5M IPO

5 years ago

For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

5 years ago

Tem­pest Ther­a­peu­tics jumps on­to Nas­daq in merg­er with strug­gling Mil­len­do Ther­a­peu­tics; Bio­haven hits $100M mile­stone as it gears up for a late-stage study in mi­graine pa­tients

5 years ago

JSR Life Sci­ences spawns new ven­ture fund; IL-2 biotech com­pletes merg­er with triv­ia com­pa­ny sub­sidiary

5 years ago

SEC opens in­quiry in­to Wall Street's SPAC ma­nia — re­port; A Chi­na-based gene ther­a­py play­er now has $80M more in the bank

5 years ago

My­ovant adds re­l­u­golix da­ta in uter­ine fi­broids ahead of June PDU­FA; Mubadala teams up with UK for $1B+ fund

5 years ago

Jeff Aron­in's Emalex rais­es $35M Se­ries C; British pro­tein degra­da­tion biotech emerges from stealth

5 years ago

Three biotechs set terms in a hunt for $475M-plus; Leap Ther­a­peu­tics earns a tri­al win across DKK1 high ex­press­ing tu­mors

5 years ago

FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study

5 years ago

Gilead and No­vo Nordisk ex­pand NASH deal with new study; Pfiz­er out-li­cens­es AD­Cs to a biotech start­up

5 years ago

New Pur­due bank­rupt­cy plan round­ly crit­i­cized as Sack­lers of­fer $4B+; Sana seals pact with Fu­ji­film for iP­SC-de­rived ther­a­pies

5 years ago

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

5 years ago

Galec­to shelves high dose of IPF drug af­ter SAE im­bal­ance; Long­time Aveo part­ner hands back HER3 an­ti­body

5 years ago

Aveo teams with Bris­tol My­ers af­ter sur­prise FDA ap­proval; Cal­ciMed­ica lines up $21M raise to ad­vance Covid-19 can­di­date

5 years ago

Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­ab

5 years ago
First page Previous page 31323334353637 Next page Last page
A service from the Financial Times